Lanoxicaps Related Published Studies
Well-designed clinical trials related to Lanoxicaps (Digoxin)
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the
pharmacokinetics of digoxin. [2014]
Effect of lacosamide on the steady-state pharmacokinetics of digoxin: results
from a phase I, multiple-dose, double-blind, randomised, placebo-controlled,
crossover trial. [2014]
The study of antiarrhythmic medications in infancy (SAMIS): a multicenter,
randomized controlled trial comparing the efficacy and safety of digoxin versus
propranolol for prophylaxis of supraventricular tachycardia in infants. [2012]
Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. [2011.03]
Digoxin for preventing or treating neonatal respiratory distress syndrome. [2011.01.19]
Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). [2010.09]
Digoxin immune fab treatment for severe preeclampsia. [2010.09]
Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects. [2010.07]
Digoxin increases peripheral chemosensitivity and the ventilatory response to exercise in normal subjects. [2010.03]
A randomized pilot study on the effectiveness and side-effect profiles of two doses of digoxin as fetocide when administered intraamniotically or intrafetally prior to second-trimester surgical abortion. [2010.01]
Effects of digoxin on muscle reflexes in normal humans. [2009.11]
Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. [2009.07]
The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind, randomized, clinical trial. [2009.04]
The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind, randomized, clinical trial. [2009.01.15]
Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. [2009.01.01]
Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. [2009.01.01]
Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. [2008.12.15]
Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. [2008.10]
The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. [2008.08]
No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects. [2008]
Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. [2007.10.18]
Digoxin bioequivalence study: determination in human plasma by microparticle enzyme immunoassay. [2007.06]
Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. [2007.03]
Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. [2006.09.05]
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. [2006.08.01]
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. [2006.08]
Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. [2006.07]
Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction. [2006.06]
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. [2006.01]
Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. [2006.01]
Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. [2005.07]
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. [2005.04]
Well-designed clinical trials possibly related to Lanoxicaps (Digoxin)
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. [2010.12.14]
Pharmacotherapy and hospital admissions before out-of-hospital cardiac arrest: a nationwide study. [2010.12]
Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). [2010.09]
[Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia]. [2010.07]
Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? [2010.07]
Fructose-1, 6-diphosphate (FDP) as a novel antidote for yellow oleander-induced cardiac toxicity: a randomized controlled double blind study. [2010.06.29]
A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. [2010.06]
Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. [2010.03]
Medication misadventures in the elderly: a year in review. [2010.02]
Efficacy of Carvedilol in Patients with Dilated Cardiomyopathy due to
Beta-thalassemia major; a Double-blind Randomized Controlled Trial. [2010]
Comparison of once-daily versus twice-daily dosing of valsartan in patients with
chronic stable heart failure. [2010]
Fructose-1, 6-diphosphate (FDP) as a novel antidote for yellow oleander-induced
cardiac toxicity: a randomized controlled double blind study. [2010]
Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study. [2009.11]
A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). [2009.06]
Management of yellow oleander poisoning. [2009.03]
BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. [2009.01.28]
Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. [2009]
Treatment of patients with heart failure and preserved ejection fraction. [2008.12]
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. [2008.09]
Treatment of heart failure with preserved systolic function. [2008.05]
Comparison of rate and rhythm control in hypertension patients with atrial fibrillation. [2008.05]
Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. [2008.04]
Medication withdrawal trials in people aged 65 years and older: a systematic review. [2008]
Mifepristone in second-trimester medical abortion: a randomized controlled trial. [2007.12]
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. [2007.06]
Initial United States experience with the Paracor HeartNet myocardial constraint device for heart failure. [2007.01]
Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. [2006.11]
Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. [2006.06.07]
Effects of Kanlijian on exercise tolerance, quality of life, and frequency of heart failure aggravation in patients with chronic heart failure. [2006.06]
A hospital perspective on the cost-effectiveness of beta-blockade for prophylaxis of atrial fibrillation after cardiothoracic surgery. [2005.12]
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). [2005.11.29]
A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. [2005.04]
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. [2005.04]
A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. [2005.03.15]
Azimilide, a novel oral class III antiarrhythmic for both supraventricular and ventricular arrhythmias. [2005.02]
When should we discontinue antiarrhythmic therapy for atrial fibrillation after coronary artery bypass grafting? A prospective randomized study. [2005.02]
Other research related to Lanoxicaps (Digoxin)
Digoxin in patients with permanent atrial fibrillation: data from the RACE II
study. [2014]
Lack of evidence of increased mortality among patients with atrial fibrillation
taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM
trial. [2013]
Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in
women with endogenous digitalis-like factor: a secondary analysis of the DEEP
Trial. [2013]
Increased mortality among patients taking digoxin--analysis from the AFFIRM
study. [2013]
Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart
rate reduction in heart failure. [2012]
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin,
valsartan, warfarin, or digoxin. [2012]
Exposure to sennoside-digoxin interaction and risk of digoxin toxicity: a population-based nested case-control study. [2011.11]
Intra-arterial and oral digoxin therapy for retinoblastoma. [2011.09]
Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study. [2011.06.01]
Digoxin use and the risk of breast cancer in women. [2011.06.01]
Changes in the pharmacokinetics of digoxin in polyuria in streptozotocin-induced diabetic mice and lithium carbonate-treated mice. [2011.06]
Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers. [2011.05]
Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. [2011.04.28]
Rapid and simultaneous measurement of midazolam, 1'-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: application to an in vivo study to simultaneously measure P-glycoprotein and cytochrome P450 3A activity. [2011.04.28]
[Effect of berberine on pharmacokinetics of digoxin after oral administration to rats]. [2011.04]
Rapid detection of oleander poisoning by Dimension Vista digoxin assay (Flex Reagent Cartridge). [2011]
Digoxin for preventing or treating neonatal respiratory distress syndrome. [2011]
Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG
data. [2011]
Use of digoxin for heart failure and atrial fibrillation in elderly patients. [2010.10]
Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin. [2010.08]
Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine, propranolol, pindolol and atenolol. [2010.03]
Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine,
propranolol, pindolol and atenolol. [2010]
Digoxin immune fab treatment for severe preeclampsia. [2010]
Macrolide-induced digoxin toxicity: a population-based study. [2009.10]
Digoxin increases peripheral chemosensitivity and the ventilatory response to exercise in normal subjects. [2009.08.28]
Effects of digoxin on muscle reflexes in normal humans. [2009.08.22]
Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. [2009.08]
Combination therapy with digoxin and diltiazem controls ventricular rate in chronic atrial fibrillation in dogs better than digoxin or diltiazem monotherapy: a randomized crossover study in 18 dogs. [2009.05]
Studies on cerebral protection of digoxin against ischemia/reperfusion injury in mice. [2009.04]
Increased risk of digoxin toxicity following hospitalization. [2009.01]
Digoxin for the treatment of chronic and acute heart failure syndromes. [2009]
Discordant results from "real-world" patient samples assayed for digoxin. [2008.12]
Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. [2008.12]
|
